HT-001

HT-001 is a proprietary, non-steroidal topical formulation developed for treating pruritus and other inflammatory skin conditions associated with Epidermal Growth Factor Receptor (EGFR) inhibitor therapy in cancer patients. It works by blocking the pro-inflammatory effects of the Substance P (SP)-NK1R pathway, a key mediator of neurogenic inflammation. The topical gel is designed to inhibit recruitment and activation of immune cells, thereby reducing inflammation. In clinical trials, HT-001 has demonstrated significant efficacy in reducing EGFR inhibitor-induced cutaneous toxicities, including pruritus, dermatitis, and hair loss, while allowing patients to maintain their full cancer treatment regimen without dose reductions.

Other names

topical aprepitant